A test paper for easily measuring the concentration of calcium in urine or the concentration of magnesium in urine colorimetrically measures the concentration of calcium in urine using a coloring agent that colors in response to calcium ions on a substrate, a magnesium ion sealing agent for preventing coloration due to magnesium ions, a pH adjustment agent, and a sensitivity adjustment agent for adjusting the sensitivity of coloration within a range of concentrations of calcium ions in urine. According to another aspect, this test paper colorimetrically measures the concentration of magnesium in urine, using a coloring agent that colors in response to magnesium ions on a substrate, a calcium ion sealing agent for preventing coloration due to calcium ions, a pH adjustment agent, and a sensitivity adjustment agent for adjusting the sensitivity of coloration within a range of concentrations of magnesium ions in urine.

A sample testing apparatus for characterizing at least one target molecule in a testing sample includes a substrate and at least one detection device over the substrate. Each detection device includes a plurality of electrodes, a plurality of data lines, and a probe. Each electrode is configured, upon reaction of the probe with one of the at least one target molecule, to sense an electrical signal, and then to transmit the electrical signal via the one data line. Each data line includes a first film layer and at least one other film layer disposed over the first film layer. The first film layer can be at a substantially same layer, and have a first composition substantially same, as the electrodes. One or more of the at least one other film layer can have a composition having a relatively lower electric resistance than the first composition.

A system for detecting COVID-19 infection, including a colorimetric sensor, an image-capturing device, and a processing unit connected to the image-capturing device. The colorimetric sensor includes an injection zone and a detection zone patterned on a paper, where the injection zone covers the detection zone by folding the paper. The injection zone is configured to inject a saliva sample acquired from a person thereon. The detection zone includes an array of chemical receptors configured to interact with the injected saliva penetrating into the detection zone. The processing unit is configured to perform a method of capturing a first image from the detection zone before injection of the saliva sample, capturing a second image from the detection zone after injection of the saliva sample, and detecting COVID-19 infection status of the person by analyzing color changes of the array of chemical receptors in the second image respective to the first image.

The present document describes a screening composition comprising a marker compound, chosen from at least one of iodine, and fluorescein; eosin Y, erythrosine, ponceau S, calcein, a catalyst, chosen from at least one boron trioxide (B.sub.2O.sub.3), potassium (K), Gallium (III) oxide (Ga.sub.2O.sub.3), Nickel (II) oxide (NiO), Vanadium (V) oxide (V.sub.2O.sub.5), magnesium oxide (MgO), a bismuth oxide chosen from bismuth subcarbonate [Bi.sub.2O.sub.2(CO.sub.3)], bismuth chloride oxide (BiClO), and bismuth oxide (Bi.sub.2O.sub.3), cesium bromide (CsBr), lanthanum (III) oxide (La.sub.2O.sub.3), molybdenum (VI) oxide (MoO.sub.3), neodymium oxide (Nd.sub.2O.sub.3), Nickel (II) carbonate anhydrous (NiCO.sub.3); and a pigment, chosen from at least one of scandium (III) oxide (Sc.sub.2O.sub.3), Lead (IV) oxide (PbO.sub.2), Sulfur (S) powder, and Tungsten (VI) oxide (WO.sub.3), chromium (III) oxide (Cr.sub.2O.sub.3), copper (II) oxide (CuO), copper (I) oxide (Cu.sub.2O), iron (III) oxide (Fe.sub.2O.sub.3), lead (II) oxide (PbO). The document also describes method of using the same.

A coagulation test device for measuring clotting time and clot characteristics of a whole blood sample under different hemostatic conditions. Results of the test are used as an aid in management of patients with coagulopathy of unknown etiology in order to help the physician determine appropriate clinical action to arrest bleeding in a patient.

The present invention relates to a method for assessing a status of a wound of a patient, comprising the steps of determining a concentration of one or more inflammatory markers selected from glucose and eotaxin-1 in a sample from the wound, wherein the sample comprises or consists of wound fluid and the one or more inflammatory markers may indicate an inflammation within the wound, ii. determining a concentration of one or more bacterial markers in the sample, wherein the one or more bacterial markers may indicate a colonization of the wound with metabolically active bacteria, iii. assessing the status of the wound based on the concentrations of the one or more inflammatory markers and the one or more bacterial markers, wherein the status of the wound is assessed as being inflamed or not inflamed and as being colonized with metabolically active bacteria or not colonized with metabolically active bacteria. This diagnostic method allows a reliable, specific and detailed assessment of the status of the wound.

Disclosed herein are methods of detecting ascorbic acid in a urine sample from a subject, including contacting at least a portion of the urine sample with a test strip including a reagent pad and detecting whether ascorbic acid is present in the urine sample by measuring an intensity of color on the reagent pad, wherein a reduction in the intensity of color on the reagent pad indicates the presence of ascorbic acid.

Provided herein is a portable test device, mass manufacture method and method of use for identification of at least one target drug of abuse. The portable detection kit can include a catalytic reagent, a solid support carrier, and an absorbent material. The colorimetric reagent and the catalytic reagent can be are affixed to the solid support carrier to form a reaction zone thereon. The colorimetric reagent and the catalytic reagent are configured to undergo chemical reaction with at least one target drug of abuse to produce a visible color change. The at least one target drug of abuse is selected from the group consisting of nicotine, cannabinoids, amphetamines, opioids, or cocaine. A target drug of abuse can be on vaping device surfaces and/or within vaping liquid formulations.

A urinalysis cassette and system that includes a toilet, into which a urinalysis cassette is inserted. The cassette is comprised of a roll of color-change-reagent strips. Each strip includes a plurality of strip sections wherein an absorbent material is imbued with color-change reagent, or onto which one or more color-change reagents are dispensed. The color-change-reagent strips are consecutive and contiguous on the roll. A cassette includes two spools arranged such that when the spools turn, the reagent strip moves from a first (source spool) to a second (waste spool). The section of the reagent strip that is between the two spools may be exposed to a urine specimen. The absorbent-material strips that have been exposed to both a urine specimen and a color-change reagent may undergo a chemical reaction. Selective-lighting illumination may be applied to absorbent-material strips that have undergone such chemical reactions to measure reflectivity of certain color wavelengths. This measurement may be expressed in terms of a digital readout, which may be displayed on a user interface.

Provided herein is an amine compound sensing marker capable of easily sensing an amine compound with high sensitivity. An amine compound sensing marker of an exemplary embodiment includes a sensing body as a retention medium where a composition containing an aggregative phosphor and a solvent is provided, the aggregative phosphor being a phosphor that aggregates and shows a fluorescence characteristics change in the presence of an amine compound. The retention medium is processed from a glass fiber.